MX364742B - Metodo de cultivo para obtener y mantener una poblacion pura o enriquecida de celulas no diferenciadas neurales y/o celulas progenitoras neurales de mamifero que con propensas a diferenciarse en celulas del linaje oligodendrocitico in vitro. - Google Patents

Metodo de cultivo para obtener y mantener una poblacion pura o enriquecida de celulas no diferenciadas neurales y/o celulas progenitoras neurales de mamifero que con propensas a diferenciarse en celulas del linaje oligodendrocitico in vitro.

Info

Publication number
MX364742B
MX364742B MX2013008208A MX2013008208A MX364742B MX 364742 B MX364742 B MX 364742B MX 2013008208 A MX2013008208 A MX 2013008208A MX 2013008208 A MX2013008208 A MX 2013008208A MX 364742 B MX364742 B MX 364742B
Authority
MX
Mexico
Prior art keywords
differentiate
cell
cells
oligodendrocyte
vitro
Prior art date
Application number
MX2013008208A
Other languages
English (en)
Other versions
MX2013008208A (es
Inventor
Tsuneo Kido
Original Assignee
Tsuneo Kido
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45529155&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX364742(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tsuneo Kido filed Critical Tsuneo Kido
Publication of MX2013008208A publication Critical patent/MX2013008208A/es
Publication of MX364742B publication Critical patent/MX364742B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/44—Thiols, e.g. mercaptoethanol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/135—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/30—Synthetic polymers
    • C12N2533/32—Polylysine, polyornithine

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Virology (AREA)

Abstract

La presente invención se refiere a una célula no diferenciada o progenitora neural humana expandible, aislada, donde la célula es una célula progenitora o célula no diferenciada, mantiene su capacidad de diferenciarse en neuronas, astrocitos, y oligodendrocitos, mantiene su capacidad para diferenciarse de células de linaje oligodendrocítico eficientemente a través de pasos subsecuentes, y la célula expresa al menos los antígenos de la superficie celular CD133 y CD140a. También se proporciona un método de cultivo in vitro de una célula progenitora o no diferenciada neural de mamífero aislada de un sistema nervioso central de mamífero, y el cultivo en sí, donde la célula conserva su capacidad para diferenciarse en neuronas, astrocitos, y oligodendrocitos y su capacidad para diferenciarse en células de linaje oligodendrocítico eficientemente. Además, se proporciona un método para tratar una condición causada por una pérdida de mielina o pérdida de oligodendrocitos como lo es una composición que comprende una célula no diferenciada neural expandible aislada o cultivada por los métodos de la invención.
MX2013008208A 2011-01-12 2012-01-12 Metodo de cultivo para obtener y mantener una poblacion pura o enriquecida de celulas no diferenciadas neurales y/o celulas progenitoras neurales de mamifero que con propensas a diferenciarse en celulas del linaje oligodendrocitico in vitro. MX364742B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161431944P 2011-01-12 2011-01-12
US201161558527P 2011-11-11 2011-11-11
PCT/IB2012/000030 WO2012095730A1 (en) 2011-01-12 2012-01-12 Culture method to obtain and maintain a pure or enriched population of mammalian neural stem cells and/or neural progenitor cells that are prone to differentiate into oligodendrocyte-lineage cells in vitro

Publications (2)

Publication Number Publication Date
MX2013008208A MX2013008208A (es) 2013-10-17
MX364742B true MX364742B (es) 2019-05-07

Family

ID=45529155

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013008208A MX364742B (es) 2011-01-12 2012-01-12 Metodo de cultivo para obtener y mantener una poblacion pura o enriquecida de celulas no diferenciadas neurales y/o celulas progenitoras neurales de mamifero que con propensas a diferenciarse en celulas del linaje oligodendrocitico in vitro.

Country Status (20)

Country Link
US (1) US8993320B2 (es)
EP (1) EP2663638B1 (es)
JP (1) JP5649745B2 (es)
KR (1) KR102099807B1 (es)
CN (2) CN109749996A (es)
AR (1) AR084835A1 (es)
AU (2) AU2012206411B2 (es)
BR (1) BR112013017685A2 (es)
CA (1) CA2821065C (es)
CL (1) CL2013002029A1 (es)
DK (1) DK2663638T3 (es)
EA (1) EA034058B1 (es)
ES (1) ES2732938T3 (es)
IL (1) IL227361B (es)
MX (1) MX364742B (es)
MY (1) MY173219A (es)
PL (1) PL2663638T3 (es)
SG (1) SG191729A1 (es)
TW (1) TWI586805B (es)
WO (1) WO2012095730A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005517717A (ja) 2002-02-15 2005-06-16 コーネル リサーチ ファンデーション， インコーポレーティッド 希突起膠細胞前駆細胞を用いた先天性髄鞘発育不全の前脳の有髄化
US9709553B2 (en) 2008-05-08 2017-07-18 University Of Rochester Treating myelin diseases with optimized cell preparations
EP2954046A4 (en) * 2013-02-06 2016-07-20 Univ Rochester Oligodendrocyte precursor cells derived from isolated pluripotent cells to treat myelin disease
CA2909637A1 (en) * 2013-04-17 2014-10-23 Salk Institute For Biological Studies Media compositions for neuronal cell culture
US10202580B2 (en) 2014-01-21 2019-02-12 Japan Science And Technology Agency Adult oligodendrocyte-type 2 astrocyte progenitor cell production method
CN105154386B (zh) * 2014-05-30 2018-04-24 中国人民解放军第二军医大学东方肝胆外科医院 人肝细胞长期维持和增殖传代培养的专用培养基和培养方法
KR101675123B1 (ko) * 2014-06-27 2016-11-14 연세대학교 산학협력단 Psa-ncam-양성 신경전구세포를 유효성분으로 포함하는 허혈성 질환 또는 신경염증 질환 치료용 조성물
KR101793722B1 (ko) 2014-08-25 2017-11-03 한국생명공학연구원 성상세포의 생산방법
CN107567494A (zh) 2015-03-04 2018-01-09 迈索布拉斯特国际有限公司 间充质干细胞的细胞培养方法
SG11201707858TA (en) * 2015-03-30 2017-10-30 Ajinomoto Kk Human serum albumin-containing culture medium for growth of neural stem cells
WO2016168586A1 (en) * 2015-04-16 2016-10-20 The Board Of Regents, The University Of Texas System Cd133+ cells and method for expanding
JP6844953B2 (ja) * 2015-04-22 2021-03-17 公益財団法人東京都医学総合研究所 アルツハイマー病研究を標的にしたグリア細胞システム
US9724432B2 (en) 2015-04-30 2017-08-08 University Of Rochester Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder
CA2990807C (en) * 2015-06-26 2023-03-14 S-Biomedics Composition for treating ischemic diseases or neuroinflammatory diseases, comprising secretome of neural precursor cells as active ingredient
CN108135839A (zh) * 2015-08-15 2018-06-08 阿斯特利亚斯生物治疗股份公司 用于治疗白质中风的干细胞衍生的少突胶质细胞祖细胞
EP3430127A4 (en) * 2016-03-18 2019-09-04 Institute of Biophysics Chinese Academy of Sciences CELL CULTURE MEDIA AND CULTURE MEDIUM SUPPLEMENT
AU2017240591B2 (en) 2016-03-30 2023-08-24 Asterias Biotherapeutics, Inc. Oligodendrocyte progenitor cell compositions
CN106929474B (zh) * 2017-03-31 2021-09-14 北京恒峰铭成生物科技有限公司 一种m2巨噬细胞诱导剂
JP7457505B2 (ja) 2017-05-10 2024-03-28 ユニバーシティー オブ ロチェスター 神経精神障害を処置する方法
KR101889228B1 (ko) * 2017-09-29 2018-08-16 연세대학교 산학협력단 Psa-ncam-양성 신경전구세포를 유효성분으로 포함하는 척수손상 치료용 조성물
CN107760649B (zh) * 2017-11-02 2021-03-30 北京全式金生物技术有限公司 一种用于人神经系统细胞培养和人多能性干细胞向神经系统细胞分化的营养添加剂
CN108070558B (zh) * 2017-11-24 2022-01-28 吉林省拓华生物科技有限公司 一种临床级神经干细胞的制备方法
KR101994640B1 (ko) 2018-03-16 2019-07-02 (주)메디노 신경줄기세포의 고효율 분리배양 방법
US20210163888A1 (en) * 2018-04-17 2021-06-03 Case Western Reserve University Induction of myelinating oligodendrocytes in human cortical spheroids
CN108624560B (zh) * 2018-06-01 2022-04-08 南京艾尔普再生医学科技有限公司 一种分化培养基及少突胶质前体细胞的制备方法
CN113646422A (zh) * 2018-09-19 2021-11-12 谱系细胞疗法股份有限公司 用于在动态悬浮培养中分化多能干细胞的方法
AU2020210757A1 (en) 2019-01-23 2021-08-05 Asterias Biotherapeutics, Inc. Dorsally-derived oligodendrocyte progenitor cells from human pluripotent stem cells
WO2022005463A1 (en) * 2020-06-30 2022-01-06 National Yang-Ming University A glia cell and neuron co-culture system and method
CN114540301B (zh) * 2020-11-20 2024-02-27 上海纽仁生物医药科技有限公司 少突胶质前体细胞亚群及其用途
US20230377685A1 (en) 2022-04-15 2023-11-23 Aspen Neuroscience, Inc. Methods of classifying the differentiation state of cells and related compositions of differentiated cells

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU632065B2 (en) * 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
DE19756864C5 (de) * 1997-12-19 2014-07-10 Oliver Brüstle Neurale Vorläuferzellen, Verfahren zu ihrer Herstellung und ihre Verwendung zur Therapie von neuralen Defekten
EP1263932A4 (en) * 2000-03-14 2004-06-23 Es Cell Int Pte Ltd EMBRYONIC CELLS AND NEURONAL STEM CELLS DERIVED THEREFROM
WO2001088104A2 (en) * 2000-05-17 2001-11-22 Geron Corporation Neural progenitor cell populations
CA2438501C (en) * 2001-02-14 2014-09-16 Leo T. Furcht Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
US9446073B2 (en) * 2005-05-15 2016-09-20 Biodontos, Llc Non-lineage committed precursor cells from the dental papillary tissue of teeth
US20080153167A1 (en) * 2006-06-21 2008-06-26 The Trustees Of Columbia University In The City Of New York In vivo amplification of neural progenitor cells
US8980630B2 (en) * 2006-06-28 2015-03-17 Rutgers, The State University Of New Jersey Obtaining multipotent amnion-derived stem cell (ADSC) from amniotic membrane tissue without enzymatic digestion
US20110236971A2 (en) * 2007-09-25 2011-09-29 Maksym Vodyanyk Generation of Clonal Mesenchymal Progenitors and Mesenchymal Stem Cell Lines Under Serum-Free Conditions
EP2379711B8 (en) * 2008-12-23 2017-03-22 BOCO Silicon Valley, Inc. Target populations of oligodendrocyte precursor cells and methods of making and using same

Also Published As

Publication number Publication date
EP2663638A1 (en) 2013-11-20
EP2663638B1 (en) 2019-03-27
EA201390801A1 (ru) 2014-06-30
AU2017216594B2 (en) 2020-01-23
AR084835A1 (es) 2013-06-26
CA2821065C (en) 2021-05-18
WO2012095730A1 (en) 2012-07-19
KR20140071512A (ko) 2014-06-11
MY173219A (en) 2020-01-07
CN109749996A (zh) 2019-05-14
TW201237169A (en) 2012-09-16
EA034058B1 (ru) 2019-12-23
BR112013017685A2 (pt) 2016-10-11
NZ611902A (en) 2016-01-29
IL227361A0 (en) 2013-09-30
NZ712598A (en) 2016-03-31
ES2732938T3 (es) 2019-11-26
AU2012206411B2 (en) 2017-05-18
AU2012206411A1 (en) 2013-07-04
US8993320B2 (en) 2015-03-31
SG191729A1 (en) 2013-08-30
PL2663638T3 (pl) 2020-02-28
CN103687941A (zh) 2014-03-26
IL227361B (en) 2018-03-29
DK2663638T3 (da) 2019-07-08
TWI586805B (zh) 2017-06-11
CL2013002029A1 (es) 2014-05-09
AU2017216594A1 (en) 2017-09-07
US20120177614A1 (en) 2012-07-12
CA2821065A1 (en) 2012-07-19
MX2013008208A (es) 2013-10-17
KR102099807B1 (ko) 2020-04-14
JP5649745B2 (ja) 2015-01-07
JP2014503219A (ja) 2014-02-13

Similar Documents

Publication Publication Date Title
MX364742B (es) Metodo de cultivo para obtener y mantener una poblacion pura o enriquecida de celulas no diferenciadas neurales y/o celulas progenitoras neurales de mamifero que con propensas a diferenciarse en celulas del linaje oligodendrocitico in vitro.
PH12016502274A1 (en) Use of small molecules to enhance mafa expression in pancreatic endocrine cells
PH12018501127A1 (en) Methods for purifying cells cderived from pluripotent stem cells
MY151979A (en) Method for producing mesenchymal stem cells from human pluripotent stem cells, and mesenchymal stem cells produced by same
WO2007149182A3 (en) Differentiation and enrichment of islet-like cells from human pluripotent stem cells
MX2021005625A (es) Metodos para aislar, cultivar y dise?ar geneticamente poblaciones de celulas inmunes para terapia adoptiva.
MY156588A (en) Systems using cell culture for production of isoprene
CA2856867C (en) Methods for producing retinal tissue and retina-related cell
EP2633036A4 (en) METHODS OF DIFFERENTIATION FOR THE PRODUCTION OF GLIAL CELL POPULATIONS
NZ709124A (en) Multipotent stem cells from the extrahepatic biliary tree and methods of isolating same
WO2012177619A3 (en) Microorganisms for producing 1,3-butanediol and methods related thereto
RU2011121843A (ru) Дифференцирование человеческих эмбриональных стволовых клеток в линию панкреатических эндокринных клеток
EP2438161A4 (en) PROCESS FOR THE PRODUCTION OF PLURIPOTENT STEM CELLS AND THEIR CULTURE PROCESS
EP2408903A4 (en) PLURIPOTENTE AND MULTIPOTENTE CELL CULTURE ON MICROWAVES
WO2015065524A3 (en) Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells
WO2011096728A3 (en) Method for proliferating stem cells by activating c-met/hgf signaling and notch signaling
EP2504425A4 (en) DIFFERENTIATION OF HUMAN EMBRYONIC AND INDUCED PLURIPOTENTER STEM CELLS
MY193954A (en) Method for manufacturing ciliary margin stem cells
WO2012088225A3 (en) Method for identifcation and culture of multipotent mesenchymal stem cells with high proliferation potential
GB2453074A (en) Differentiation of primate pluripotent cells to hepatocyte-lineage cells
AR083934A1 (es) Capa de pichia kluyveri y sus aplicaciones
MX2021014681A (es) Células progenitoras de oligodendrocitos inducidas por la caja hmg relacionada con sry 9.
WO2015108944A3 (en) Stem cell-derived hepatocytes in co-culture and uses thereof
WO2014074770A3 (en) Balanced mixotrophy methods
WO2010013906A3 (ko) 인간 줄기세포에서 고활성 줄기세포를 분리하는 방법 및 상기 방법에 의해 분리된 고활성 줄기 세포

Legal Events

Date Code Title Description
FG Grant or registration